AbbVie Inc. v. Hetero Labs Limited et al
| AbbVie Inc. |
| Hetero Labs Limited, Hetero Labs Limited Unit-V and Hetero USA Inc. |
| 1:2024cv00151 |
| February 5, 2024 |
| US District Court for the District of Delaware |
| Jennifer L Hall |
| Patent - Abbreviated New Drug Application(ANDA) |
| 35 U.S.C. ยง 271 Patent Infringement |
| None |
Docket Report
RSS Track this Docket
This docket was last retrieved on March 5, 2024. A more recent docket listing may be available from PACER.
| Document Text |
|---|
Filing 11
SO ORDERED, re (7 in 1:24-cv-00153-JLH, 194 in 1:22-cv-01423-JLH, 7 in 1:24-cv-00154-JLH, 10 in 1:24-cv-00151-JLH, 10 in 1:24-cv-00152-JLH) Stipulation and Order regarding Consolidation for all purposes. Signed by Judge Jennifer L. Hall on 3/5/2024. Associated Cases: 1:22-cv-01423-JLH, 1:24-cv-00151-JLH, 1:24-cv-00152-JLH, 1:24-cv-00153-JLH, 1:24-cv-00154-JLH(ceg)
|
| Case associated with lead case: Create association to 1:22-cv-01423-JLH. ALL FUTURE FILINGS SHALL BE MADE IN LEAD CASE NO. 1:22-cv-01423-JLH ONLY. (ceg) |
| Filing 10 STIPULATION and [Proposed] Order Regarding Consolidation by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (Dellinger, Megan) |
| Filing 9 SUMMONS Returned Executed by AbbVie Inc..Hetero Labs Limited Unit-V served on 2/23/2024, answer due 3/15/2024. (Tigan, Jeremy) |
| Filing 8 SUMMONS Returned Executed by AbbVie Inc..Hetero Labs Limited served on 2/23/2024, answer due 3/15/2024. (Tigan, Jeremy) |
| Filing 7 SUMMONS Returned Executed by AbbVie Inc..Hetero USA Inc. served on 2/23/2024, answer due 3/15/2024. (Tigan, Jeremy) |
| Filing 6 Summons Issued as to Hetero Labs Limited, Hetero Labs Limited Unit-V, and Hetero USA Inc. on 2/23/2024. (Attachments: #1 Summons Issued Hetero Labs Limited, #2 Summons Issued Hetero USA Inc.)(jfm) |
| Case Assigned to Judge Jennifer L. Hall. Please include the initials of the Judge (JLH) after the case number on all documents filed. Associated Cases: 1:24-cv-00151-JLH, 1:24-cv-00152-JLH, 1:24-cv-00153-JLH, 1:24-cv-00154-JLH (rjb) |
| Filing 5 Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by AbbVie Inc. (smg) |
| Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,690,845 B2; 11,690,854 B2. (smg) |
| Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: N/A Date of Expiration of Patent: U.S. Patent No. 11,690,845: August 27, 2040; U.S. Patent No. 11,690,854: April 19, 2038.Thirty Month Stay Deadline: 1/23/2026. (smg) |
| Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (smg) |
| Filing 1 COMPLAINT for PATENT INFRINGEMENT filed against Hetero Labs Limited, Hetero Labs Limited Unit-V, and Hetero USA Inc. ( Filing fee $ 405, receipt number ADEDC-4330975.) - filed by AbbVie Inc. (Attachments: #1 Exhibit A, #2 Exhibit B, #3 Civil Cover Sheet)(smg) |
| No Summons Issued. (smg) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
